FDA Approved: METHYLPHENIDATE — Supplemental Application (Sandoz Inc)

View source ↗

Summary

FDA approved a supplemental application for methylphenidate submitted by Sandoz Inc under NDA 021284, marking an additional approval for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Narcolepsy

Drugs mentioned

• METHYLPHENIDATE HYDROCHLORIDE (METHYLPHENIDATE HYDROCHLORIDE)
• Methylphenidate (Methylphenidate)

Snippet

SUPPL AP for METHYLPHENIDATE (METHYLPHENIDATE)